About: Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $45.09 (+4.62%)
COAG NASDAQ Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. Common Stock share price
Atividade de preço de COAG
Último preço
$ 45,090
Variação (24h)
1,99 USD (4,62%)
Volume
498.88K
Volume (média 4 sem.)
-
Abertura
$ 45,00
Variação do dia
$ 41,96 - $ 45,11
Fechamento anterior
$ 43,10
Último negócio
04 Nov, 9:00 pm GMT+0
Atrasado
04 Nov, 9:00 pm GMT+0
COAG price performance
Atrasado
04 Nov, 9:00 pm GMT+0
COAG details
quote.marketSignals